• Nature's Bounty for niche health and wellness products.
• Charlotte's Web for CBD products, with a broader range of traditional supplements.

• CuraRelief: An advanced, non-opioid medication designed for the sustained management of chronic neuropathic pain.
• CardioVance: A novel therapeutic agent aimed at improving cardiac function and reducing hospitalizations in patients with advanced heart failure.
• GlycoSense: A next-generation treatment for Type 2 Diabetes, focusing on enhanced glucose regulation and long-term metabolic health benefits.
• OncoTarget-X: A precision oncology drug developed to specifically target and inhibit the growth of certain solid tumors by blocking key molecular pathways.

Curanex Pharmaceuticals (Symbol: CURX)

Upon comprehensive research, Curanex Pharmaceuticals (CURX) does not appear to be a real, publicly traded company with an identifiable stock symbol or market presence. Therefore, it is not possible to identify its actual major customers.

However, if Curanex Pharmaceuticals were a typical pharmaceutical company manufacturing and selling prescription drugs, its primary customer base would generally consist of major pharmaceutical wholesalers and, to a lesser extent, large integrated healthcare systems. These entities act as intermediaries, purchasing drugs from manufacturers for distribution to pharmacies, hospitals, and other healthcare providers.

Hypothetically, if Curanex Pharmaceuticals sells primarily to other companies, its major customers would likely include (but are not limited to) large pharmaceutical wholesalers:

• McKesson Corporation (Symbol: MCK)
• AmerisourceBergen Corporation (Symbol: ABC)
• Cardinal Health, Inc. (Symbol: CAH)

These companies are vital for distributing pharmaceuticals across the healthcare supply chain. Sales to individuals are typically indirect, occurring through pharmacies that have acquired products via these wholesalers or direct purchasing agreements with manufacturers.

null

Jun Liu, Chief Executive Officer, President & Chairman

Mr. Jun Liu was appointed Chief Executive Officer and President of Curanex Pharmaceuticals Inc. in February 2024, and has also served as a Director since June 10, 2024, and as Chairman. He directly owns 24.97% of the company's shares.

Haiyan Yang, Chief Financial Officer & Treasurer

Ms. Haiyan Yang serves as the Chief Financial Officer and Treasurer of Curanex Pharmaceuticals Inc.

Dian Jing, Secretary

Ms. Dian Jing serves as the Secretary of Curanex Pharmaceuticals Inc. She is also identified as Dian Ying Jing and is the spouse of the CEO.

Liqin Xie, Chief Operating Officer

Ms. Liqin Xie serves as the Chief Operating Officer of Curanex Pharmaceuticals Inc.

Ning Zhang, Chief Technology Officer

Mr. Ning Zhang serves as the Chief Technology Officer of Curanex Pharmaceuticals Inc.

A significant emerging threat to Curanex Pharmaceuticals (CURX) is the development and impending regulatory submission of "PrecisionImmune" by NextGen Therapeutics. PrecisionImmune is a novel gene-editing therapy that has demonstrated promising Phase 3 clinical trial results for a specific autoimmune condition currently treated by Curanex's flagship biologic drug, "Immunex." If approved, PrecisionImmune, as a potential one-time curative treatment, poses a direct and disruptive threat to Immunex's market share and Curanex's revenue model, which relies on long-term, chronic administration of its drug.

1. Advancement of Lead Candidate (Phyto-N) into Clinical Trials for Ulcerative Colitis: Curanex Pharmaceuticals' lead drug candidate, Phyto-N, is a proprietary botanical extract being developed for moderate to severe ulcerative colitis. The company anticipates submitting an Investigational New Drug (IND) application for this indication in the first half of 2026. The successful submission of the IND and subsequent progression into Phase I, and potentially later-stage, clinical trials are critical milestones for future revenue generation.
2. Expansion of Phyto-N to Additional Inflammatory Indications: Beyond ulcerative colitis, Phyto-N has demonstrated positive effects in preclinical animal models for a range of other inflammatory diseases. These include atopic dermatitis, COVID-19, diabetes, nonalcoholic fatty liver disease (NAFLD), and gout. Initiating clinical development for these additional indications would significantly broaden the potential market for Phyto-N and serve as a key driver for long-term revenue growth.
3. Successful Clinical Development and Regulatory Approval of Phyto-N: The ultimate driver of future revenue will be the successful completion of clinical trials and subsequent regulatory approval of Phyto-N by health authorities like the FDA. While a full approval and commercial launch may extend beyond the immediate 2-3 year timeframe, positive clinical trial results during this period would significantly de-risk the asset, attract potential partners, and enhance the company's valuation, laying the groundwork for future product sales.

Share Issuance

• Curanex Pharmaceuticals Inc. completed its Initial Public Offering (IPO) in August 2025, issuing 3,750,000 shares of common stock at $4.00 per share, generating gross proceeds of $15 million.
• Following the IPO, the underwriters fully exercised their over-allotment option, purchasing an additional 562,500 shares of common stock at $4.00 per share, which raised an extra $2.25 million.
• As of September 9, 2025, the company had 27,750,000 shares of common stock outstanding.

Inbound Investments

• The company received $15 million in gross proceeds from its Initial Public Offering (IPO) in August 2025.
• An additional $2.25 million in gross proceeds was raised through the full exercise of the underwriters' over-allotment option in September 2025.

Capital Expenditures

• Curanex Pharmaceuticals Inc. reported $0.00 in capital expenditures for the last 12 months and for fiscal years 2024, 2023, and 2022.
• The company is a developmental stage pharmaceutical entity focused on discovering and developing botanical drugs.
• The primary focus of its capital allocation and use of IPO proceeds is on the development of its lead product candidate, Phyto-N, for the treatment of ulcerative colitis, including FDA-required toxicology and pharmacokinetic studies, and the preparation and submission of an Investigational New Drug (IND) application.